tradingkey.logo

Bristol Myers Squibb And Pfizer Announce Direct-To-Patient Eliquis® (Apixaban) Option

ReutersJul 17, 2025 11:57 AM

Bristol-Myers Squibb Co BMY.N:

  • BRISTOL MYERS SQUIBB AND PFIZER ANNOUNCE DIRECT-TO-PATIENT ELIQUIS® (APIXABAN) OPTION

  • BRISTOL-MYERS SQUIBB CO - ELIQUIS 360 SUPPORT PROGRAM NOW OFFERS ELIQUIS TO CASH-PAYING PATIENTS AT MORE THAN 40% DISCOUNT TO CURRENT LIST PRICE

  • BRISTOL-MYERS SQUIBB CO - ELIQUIS OFFERED AT OVER 40% DISCOUNT TO LIST PRICE

  • BRISTOL-MYERS SQUIBB CO - ELIGIBLE U.S. PATIENTS CAN PURCHASE ELIQUIS DIRECTLY FROM SEPTEMBER 8

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI